Evidence map›Paper›PMID 8605098›Full record

ArticleBritish journal of cancer1996

Potential prognostic value in human breast cancer of cytosolic Nme1 protein detection using an original hen specific antibody.

C Toulas, J Mihura, C de Balincourt, B Marques, E Marek, G Soula, H Roche, G Favre

Open access · bronzeAbstract read
In one paragraph

Article in British journal of cancer, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Metastasis suppressor genes.Histology and histopathology · 2013
    Review
  4. Review
  5. Article
  6. Nm23/nucleoside diphosphate kinase in human cancers.Journal of bioenergetics and biomembranes · 2000
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

C ToulasClaudius Regaud Comprehensive Center, Toulouse, France.
J Mihura
C de Balincourt
B Marques
E Marek
G Soula
H Roche
G Favre
Institut Claudius Regaud · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The metastasis-suppressor nme gene (also called nm23), first identified in murine melanoma cells, exists as two forms in human: nme1 and nme2. However, only the lack of expression of nme1 has been related to distant metastasis appearance in human breast cancer. The aim of this work was first to raise specific antibodies to allow the analysis of Nme1 and then, with this specific tool, to evaluate the predictive value of Nme1 detection in cytosolic extracts of human breast tumours. We obtained a hen antibody that specifically reacts with Nme1 without any cross-reaction with Nme2. We analysed the expression of the protein in 59 human breast tumours and found a significant relationship between this expression and oestrogen receptor status (P<0.001). Moreover, Nme1 expression is related to metastasis-free survival (P<0.001) and survival of patients (P<0.001). The determination of Nme1 expression in primary tumours using our antibody should be an interesting predictive test of the metastasis for clinical investigations.

Indexed as

Monomeric GTP-Binding ProteinsAnimalsAntibody SpecificityBreast NeoplasmsChickensCytosolFemaleGenes, erbB-2HumansNeoplasm MetastasisNM23 Nucleoside Diphosphate KinasesNucleoside-Diphosphate KinasePrognosisSurvival RateTranscription FactorsMonomeric GTP-Binding ProteinsNM23 Nucleoside Diphosphate KinasesNME1 protein, humanNME2 protein, humanNucleoside-Diphosphate KinaseTranscription Factors

Identifiers

PMID8605098
PMCPMC2074342
OpenAlexW2116671643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.